R&D Changing Faces: Pharma and biotech, January 2026 The new year brought a slew of new faces in the pharma and biotech world, especially in the top jobs, with a number of CEO changes at biotech firms.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
R&D Strategies for creating an ecosystem to support early-stage ... Learn how to foster growth for early-stage biotech companies through innovative ecosystem strategies and valuable CDMO collaborations
R&D Navigating the new ICH E6 (R3): Key changes for sponsors These new regulations for running clinical trials in the UK will be a legal requirement from 28th April 2026.
R&D Sponsored Organoid neurotoxicity testing gains momentum Organoid-based approaches may become an integral part of neurological safety testing, offering a clearer view of risk.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
News NHS to offer Wegovy to a million more people in England The NHS in England will make Novo Nordisk's Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.